The goal of this clinical trial is to learn if low-level laser therapy (also called photobiomodulation) works to treat knee or heel pain in physically active children and adolescents with Osgood-Schlatter disease or Sever disease. It will also learn about the safety of this treatment. The main questions it aims to answer are: 1. Does low-level laser therapy lower pain more than a sham (placebo) laser treatment? 2. Does low-level laser therapy improve daily and sport-related function more than a sham laser treatment? 3. What medical problems, if any, do participants have during the study? Researchers will compare active low-level laser therapy to a sham (placebo) laser treatment. The sham treatment looks and feels the same but does not deliver therapeutic light. This comparison will show whether the laser therapy works better than placebo. Participants will: * Complete screening and a baseline visit * Be randomly assigned to active laser therapy or sham laser therapy * Receive a series of treatment sessions over \[2 weeks\] * Answer short questionnaires about pain and function at baseline and follow-up visits * Have ultrasound imaging and/or provide blood or urine samples for research measurements Both participants and the study team who assess outcomes will not know which treatment group each participant is in until the study ends.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Recruitment feasibility: proportion of eligible participants enrolled
Timeframe: From first screening contact through completion of enrollment.
Retention feasibility: proportion completing post-intervention and follow-up assessments
Timeframe: Baseline to post-intervention (≈2 weeks) and baseline to follow-up (≈3 months).
Adherence feasibility: proportion of intervention sessions completed
Timeframe: During the 2-week intervention period.
Data completeness feasibility: proportion of complete datasets for key clinical outcomes
Timeframe: Baseline to follow-up (≈3 months).
Safety and tolerability: number and type of adverse events related to the intervention
Timeframe: During the 2-week intervention period.